Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Oct 2:136:111999.
doi: 10.1016/j.ijscr.2025.111999. Online ahead of print.

A unique pediatric thoracic fibrosarcoma: Case report and successful therapeutic strategy

Affiliations
Case Reports

A unique pediatric thoracic fibrosarcoma: Case report and successful therapeutic strategy

Khaled Alomar et al. Int J Surg Case Rep. .

Abstract

Introduction and significance: Congenital Infantile Fibrosarcoma (CIFS) is an exceptionally rare pediatric malignancy, representing approximately 10 % of all soft tissue cancers in young children. Its clinical manifestations vary according to tumor location. When tumors occur in unusual anatomical sites, symptoms may be misleading and delay proper diagnosis and treatment.

Case presentation: We report an 11-month-old male with a month-long persistent dry cough and high fever unresponsive to antibiotics. Chest CT revealed a pleural mass with mild effusion. Thoracotomy achieved complete excision (R0). Histopathology showed low-grade fibrosarcoma; immunohistochemistry was positive for Vimentin and SMA, focally CD34, and negative for S100, Desmin, and Myogenin, with low Ki-67 (<3 %). ETV6-NTRK3 fusion testing was unavailable. The patient received six cycles of adjuvant VAC chemotherapy and tolerated treatment well, with only mild transient neutropenia.

Clinical discussion: Diagnosis depends on histopathological and immunohistochemical analysis, as CIFS mimics several other soft tissue sarcomas. Our review of medical literature found no prior cases of CIFS originating in the pleura, underlining the uniqueness of this case. Management followed a standard multidisciplinary approach consisting of complete surgical excision and adjuvant chemotherapy (VAC protocol). At 12-month follow-up, the patient remained recurrence-free.

Conclusion: Persistent pneumonia-like symptoms unresponsive to standard treatment in infants should prompt consideration of underlying malignancy. Early recognition and prompt management are essential for improving outcomes in such rare presentations.

Keywords: CaseReport-pediatric-fibrosarcoma; Congenital-infantile.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Axial chest computed tomography (CT) scan demonstrating a left-sided thoracic mass (green arrow) associated with mediastinal shift toward the right side (yellow arrow). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2
Fig. 2
Intraoperative image showing the completely resected tumor.
Fig. 3
Fig. 3
Hematoxylin and eosin (H&E) staining revealing a spindle cell neoplasm consistent with low-grade fibrosarcoma.
Fig. 4
Fig. 4
Immunohistochemical analysis: A: Diffuse positivity for vimentin. B: Negative staining for S100 protein. C: Negative staining for desmin. D: Ki-67 proliferation index exceeding 3 % of tumor cells.

References

    1. Al-Ibraheemi A., Zhou Y., Rullo E., Alaggio R. What is new in fibroblastic/myofibroblastic tumors in children. Virchows Arch. Advance online publication. 2024 doi: 10.1007/s00428-024-03981-8. Nov 16. - DOI
    1. González-López J., Rubio-Martínez L.A., Atarés M., Amaya J.V., Huart M.C., Mayordomo-Aranda E., Giner F. Novel EVI5::BRAF Gene Fusion in Infantile Fibrosarcoma: A Case Report and Review of Literature. Int. J. Mol. Sci. 2025;26(3):1182. doi: 10.3390/ijms26031182. Published 29 Jan 2025. - DOI - PMC - PubMed
    1. Laetsch T.W., Voss S., Ludwig K., Hall D., Barkauskas D.A., Dubois S.G., Ronan J., Rudzinski E.R., Memken A., Robinson K., Sorger J., Reid J.M., Bhatla T., Crompton B.D., Church A.J., Fox E., Weigel B.J. Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children’s Oncology Group ADVL1823) J. Clin. Oncol. 2025 Apr;43(10):1188–1197. doi: 10.1200/JCO-24-01854. - DOI - PMC - PubMed
    1. Corral Sánchez M.D., Jiménez Carrascoso R., Rubio Aparicio P., Plaza López de Sabando D., Sastre Urgelles A., Pozo-Kreilinger J.J., López Gutiérrez J.C., Gómez Cervantes M., Ortiz Cruz E.J., Pérez-Martínez A. Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series. Clin. Transl. Oncol. 2023;25(11):3307–3311. doi: 10.1007/s12094-023-03175-9. - DOI - PubMed
    1. Laetsch T.W., Voss S., Ludwig K., Hall D., Barkauskas D.A., DuBois S.G., et al. Larotrectinib in newly diagnosed infantile fibrosarcoma and other pediatric NTRK fusion-positive solid tumors. J. Clin. Oncol. 2025 Apr;43(10):1188–1197. doi: 10.1200/JCO-24-01854. Epub 2024 Dec 9. - DOI - PMC - PubMed

Publication types

LinkOut - more resources